Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
223.34
-5.07 (-2.22%)
Oct 8, 2026, 3:11 PM EDT - Market open
Ascendis Pharma Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $273 | Buy | Reiterates | $273 | +22.24% | Oct 3, 2026 |
| Barclays | Barclays | Buy Maintains $329 | Buy | Maintains | $329 | +47.31% | Sep 30, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $300 | Buy | Maintains | $300 | +34.32% | Sep 25, 2026 |
| Wedbush | Wedbush | Buy Maintains $327 | Buy | Maintains | $327 | +46.41% | Sep 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $344 | Buy | Reiterates | $344 | +54.03% | Sep 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $304 | Buy | Maintains | $304 | +36.12% | Sep 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 15, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $319 | Buy | Maintains | $319 | +42.83% | Sep 15, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.